Provided by Tiger Trade Technology Pte. Ltd.

ArTara Therapeutics, Inc.

3.85
-0.0500-1.28%
Post-market: 3.980.1300+3.38%19:57 EDT
Volume:238.40K
Turnover:921.28K
Market Cap:227.52M
PE:-2.84
High:3.95
Open:3.91
Low:3.81
Close:3.90
52wk High:7.82
52wk Low:3.02
Shares:59.10M
Float Shares:57.41M
Volume Ratio:0.72
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3535
EPS(LYR):-1.3409
ROE:-45.80%
ROA:-28.82%
PB:1.41
PE(LYR):-2.87

Loading ...

Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch

TIPRANKS
·
Aug 22

Spruce Biosciences Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 12

Protara: Strategic Trial Redesign and Strong TARA-002 Profile Support Buy Rating with Unchanged $27 Price Target

TIPRANKS
·
Aug 12

Savara Q2 Loss Widens as Operating Expenses Rise

Reuters
·
Aug 12

Protara Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Protara Therapeutics Q2 EPS USD -0.36

Reuters
·
Aug 11

Protara Net Loss Widens to $21.7 Million in Q2 FY26; R&D Expenses Rise to $17 Million

Reuters
·
Aug 11

Protara Therapeutics Q2 Operating Expenses USD 23.324 Million

THOMSON REUTERS
·
Aug 11

Protara Therapeutics - Expects to Submit Bla for Tara-002 in Lms in 2H 2027

THOMSON REUTERS
·
Aug 11

Protara Therapeutics - on Track to Report Interim Results from Thrive-3 Trial in Q4 2026

THOMSON REUTERS
·
Aug 11

Press Release: ROYAL Caribbean GROUP Appoints TARA BUNCH to BOARD of Directors

Dow Jones
·
Jul 21

Protara Therapeutics CEO Jesse Shefferman Disposes of 215,687 Common Shares for $882,156.83

Reuters
·
Jul 02

Protara Therapeutics CMO Nicacio Resigns Effective June 26, 2026

Reuters
·
Jun 30

Protara Therapeutics shareholders elect three directors at annual meeting

Reuters
·
Jun 16

IDT names William Conkling to board, taps him as audit committee chair

Reuters
·
Jun 12

Protara Therapeutics - Enters Sales Agreement With TD Cowen for Common Stock Offering - SEC Filing

THOMSON REUTERS
·
May 29

Protara Therapeutics : Oppenheimer Raises Target Price to $28 From $25

THOMSON REUTERS
·
May 20

Protara Therapeutics (TARA) Receives a Buy from Oppenheimer

TIPRANKS
·
May 20

Peaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential

TIPRANKS
·
May 20

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

GlobeNewswire
·
May 18